State Street's passive 7.4% stake is consistent with index fund and institutional ownership patterns. Monitor the next 13F filing for any material changes in position size, and watch for any future 13D conversion if State Street's investment approach shifts.
SRPT drugs
SRPT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $16.42entry
- T+1 · 6d ago +1.58%α +0.26% · $16.68
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp filed a new Schedule 13G disclosing a 7.4% passive stake in Sarepta Therapeutics as of September 30, 2026. This follows State Street's prior 13G filing in August 2026 and comes five days after Sarepta raised its full-year revenue guidance. The filing confirms a passive investment intent with no control-related purpose.
Key Financial Metrics
Key Facts
- State Street Corp filed a new Schedule 13G on November 10, 2026, disclosing beneficial ownership of 7,412,275 shares of Sarepta Therapeutics common stock as of September 30, 2026.
- The stake represents approximately 7.4% of shares outstanding based on the 7,412,275 shares reported.
- State Street certifies the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing control of the issuer.
- This filing follows State Street's prior 13G filing on August 7, 2026, indicating a continued passive position.
- The filing comes five days after Sarepta raised its full-year net product revenue guidance to $1.25B-$1.3B on November 5, 2026.
Financial Impact
State Street holds 7,412,275 shares; at a $1.9B market cap this stake is valued at approximately $140M.
Risk Factors
- No activist intent is indicated; the filing explicitly certifies passive investment purpose.
- The stake size is moderate for an institutional holder and does not signal unusual conviction beyond normal portfolio allocation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000721 |
| Document: 0000093751-26-000721-index.html | 0000093751-26-000721 |
| Document: 0000093751-26-000721.txt | 0000093751-26-000721 |
Track record
9 reports on SRPT
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $16.07 Now $15.13 −5.85% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $16.42 Now $15.13 −7.86% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $17.82 Now $15.13 −15.10% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $18.54 Now $15.13 −18.39% settles Dec 2
- Jul 27, 202616w ago 8-K Neutral 3/10 Entry $15.89 to $18.13 Now $15.13 −4.78% ▲ +14.10% +10.80% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $15.00 to $20.52 Now $15.13 +0.87% ▲ +36.80% +34.91% vs SPY
- Jun 4, 202623w ago 8-K Neutral 3/10 Entry $15.75 to $19.18 Now $15.13 −3.94% ▲ +21.78% +19.92% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $20.89 to $16.67 Now $15.13 −27.56% ▼ −20.18% −25.14% vs SPY
- Feb 25, 202637w ago 8-K Mixed 7/10 Entry $17.45 to $21.68 Now $15.13 −13.30% ▲ +24.24% +30.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers